Navigation Links
Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
Date:1/23/2008

-- Peregrine Has Now Received Regulatory Approval for Three Phase II Cancer

Trials to Study Bavituximab in Combination with Chemotherapy -- -- New Clinical Trial Will Evaluate Anti-Tumor Activity of Bavituximab in

Combination with Carboplatin and Paclitaxel --

TUSTIN, Calif., Jan. 23 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that its Phase II clinical protocol to study bavituximab in combination with chemotherapy in patients with advanced breast cancer has been approved by the Drug Controller General of India (DCGI). The primary objective of the multi-center clinical trial is to assess the overall response rate to the combination of bavituximab with carboplatin and paclitaxel, chemotherapy drugs commonly used in the treatment of breast cancer.

In the trial's two-stage design, up to 15 patients with advanced breast cancer will be enrolled initially. The study will then be expanded up to a total of 46 patients if promising results are observed. Secondary objectives of the study include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. Patients may continue to receive bavituximab alone after completion of chemotherapy as long as the cancer does not progress and side effects are acceptable.

"We are eager to begin this new trial because we saw encouraging signs of activity against advanced breast cancer in our bavituximab pilot combination therapy study, where two patients treated with bavituximab and these same chemotherapy agents achieved objective tumor r
'/>"/>

SOURCE Peregrine Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
2. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
3. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
4. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
5. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
6. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
7. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
8. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
9. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... N.C., Oct. 20, 2014  BioPontis Alliance for ... both philanthropies, announced today the creation of a ... treatment of the rare disease known as Charcot- ... its alliance model earlier this month. Today,s partnership ... a collaborative model where researchers and all CMT ...
(Date:10/19/2014)... 19, 2014  Henry Schein, Inc. (NASDAQ: ... products and services to office-based dental, animal health and ... Iwase Dental Supply, Inc., a leading full-service provider of ... Henry Schein,s entrance into Japan , ... increases to 28 the number of countries in which ...
(Date:10/17/2014)... 17, 2014 With the recent changes ... has come across several challenges in creating and ... globalization.  The Medical Affairs ... to providing benchmarking and best practices across critical ... a service composed of three stages: 1) member-driven ...
Breaking Medicine Technology:The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3Henry Schein Enters Japan With Investment in Iwase Dental Supply 2Henry Schein Enters Japan With Investment in Iwase Dental Supply 3Henry Schein Enters Japan With Investment in Iwase Dental Supply 4Henry Schein Enters Japan With Investment in Iwase Dental Supply 5Early Key Findings from the Medical Affairs Consortium Research 2
... /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: ... R&D outsourcing company with operations in China and the ... results for the third quarter of 2011 after the ... 2011 (which will be Friday morning, November 11, 2011 ...
... CLOSTER, N.J., Oct. 25, 2011 Ericom Software, ... virtualization solutions, today announced the availability of Ericom ... the AccessNow HTML5 product family. AccessNow for Enterprise ... desktops within leading enterprise portals, including IBM WebSphere ...
Cached Medicine Technology:WuXi PharmaTech Schedules Third-Quarter 2011 Earnings Release 2Ericom AccessNow™ for Enterprise Portals - Secure, Portal-based, HTML5 Web Access to Windows Applications, Desktops and Services 2Ericom AccessNow™ for Enterprise Portals - Secure, Portal-based, HTML5 Web Access to Windows Applications, Desktops and Services 3
(Date:10/20/2014)... My Clients Plus ( http://www.MyClientsPlus.com ) today ... new module enables easy administration and routing of follow-up ... , This application allows users such as Therapists to ... to-do item to a specific client, categorize tasks the ... reminders for follow-ups. It's designed to enable easy ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 ... Voicheck as Assistant Director of their CentralSource ... in managing the innovative turnkey drug sourcing, distribution, ... Matthew brings over 12 years of industry experience, ... Myoderm at the peak of their international success ...
(Date:10/20/2014)... Based on a proprietary chromatid-specific ... assays capable of determining DNA sequence, location and ... three dimensions of high-resolution data, dGH assays are ... range of disease-causing genetic rearrangements, including chromosomal inversions ... tools, including today’s advanced sequencing technologies. , According ...
(Date:10/20/2014)... Ohio (PRWEB) October 20, 2014 Unveiled at ... new Strategic Direction Scorecard conservatively estimates member hospital ROI on ... spent on dues, The Center provides $12.50 in value to ... is (Member Value – Member Dues)/Member Dues. , “This ... at this number and we think the methodology is really ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Houston plastic ... present the key elements of his innovative True ... to plastic surgery residents and faculty at The ... where he, too, was once a medical student. Patronella, ... largest private cosmetic plastic surgery practices in Texas, ...
Breaking Medicine News(10 mins):Health News:My Clients Plus Announces New Workflow Management Software 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2
... of actual resveratrol plus 95% OPCs ... and three ... manufacturer,Renaissance Health Publishing, LLC, is disappointed and confused as to ... of Revatrol, and calls on the for-profit laboratory,to remove the ...
... often be the smarter choice, study suggests , MONDAY, Nov. ... symptoms of throat infection, surgery to remove the tonsils is ... watching and waiting to see if symptoms resolve, a Dutch ... University Medical Center Utrecht compared 151 children, ages 2 to ...
... McCandliss, a psychologist at the Sackler Institute for Developmental ... Weill Cornell Medical College, has received a commendation by ... of a Presidential Early Career Award for Scientists and ... by the U.S. government for outstanding scientists and engineers ...
... new article appearing in American Journal of Transplantation describes ... of organ rejection in kidney transplants. The technique, which ... examining DNA sequences, defines how major causes of organ ... behavior. The study is the first to show how ...
... Booker, II, CPA, Presented with Charles Kopke,Medal ... Nov. 19 The American,Diabetes Association (ADA), ... fight against diabetes, announced today that G. ... Arkansas, received the,Association,s prestigious Charles Kopke Medal ...
... an,important step toward protecting patient access to essential ... Fracture Prevention and,Osteoporosis Testing Act of 2007," sponsored ... a reversal of drastic Medicare cuts,to DXA (dual ... the gold standard for measuring bone mass to ...
Cached Medicine News:Health News:ConsumerLab.com Study On Revatrol NOT Based on Current Formulation - the Revatrol Sample Used Was More Than Nine Months Out-Of-Date, says Renaissance Health Publishing 2Health News:ConsumerLab.com Study On Revatrol NOT Based on Current Formulation - the Revatrol Sample Used Was More Than Nine Months Out-Of-Date, says Renaissance Health Publishing 3Health News:Tonsillectomy Not Always Cost-Effective for Kids' Throat Woes 2Health News:White House awards Weill Cornell's Bruce McCandliss highest honor for early career scientists 2Health News:Breakthrough in organ rejection diagnosis examines gene behavior 2Health News:Bill Booker Receives American Diabetes Association's Distinguished Service Award 2Health News:Bill Booker Receives American Diabetes Association's Distinguished Service Award 3Health News:Congress Moves to Protect Bone Health 2
Allows for custom orientation of specimen...
Honing compound for knife sharpening, 6 grams net...
Standard knife with box, C profile...
... sectioning work, it is necessary to cool a ... can be fitted to most microtomes and will ... lower, depending on conditions. The equipment consists of ... cooling stage is best suited for operation with ...
Medicine Products: